Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 64.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,599 shares of the biopharmaceutical company's stock after purchasing an additional 625 shares during the period. Aptus Capital Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $1,139,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Capital International Investors boosted its stake in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the period. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $802,036,000. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Amundi boosted its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in shares of Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after acquiring an additional 393,997 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on REGN. UBS Group cut their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Guggenheim reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $892.60.

Regeneron Pharmaceuticals Price Performance

REGN traded down $19.89 during trading on Friday, hitting $527.78. The company's stock had a trading volume of 1,498,740 shares, compared to its average volume of 769,971. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The firm has a market capitalization of $57.70 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The business's fifty day simple moving average is $613.08 and its 200 day simple moving average is $695.07.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the firm earned $9.55 EPS. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.